Start with its own history
At 38.98×, CMPUY is 14.9% below its 10-observation annual average. A lower multiple can reflect a lower price, higher earnings, or weaker growth expectations—not necessarily a bargain.

Current valuation, historical context, and peer comparisons.
Current P/E ratio
38.98×
14.9% belowthe 10-year annual average
Price and EPS in quote currency. Calculation details
Investors are paying 38.98 for every 1 of reported earnings per share.
Annual period-end data · 13 observations
| Period end | P/E | Change |
|---|---|---|
| Dec 31, 2024 | 32.48× | -24.8% |
| Dec 31, 2023 | 43.18× | +69.2% |
| Dec 31, 2022 | 25.52× | -52.7% |
| Dec 31, 2021 | 53.90× | -6.7% |
| Dec 31, 2020 | 57.79× | +23.3% |
| Dec 31, 2019 | 46.88× | +122.7% |
| Dec 31, 2018 | 21.05× | -76.6% |
| Dec 31, 2017 | 90.00× | +108.0% |
| Period end | P/E | Change |
|---|---|---|
| Dec 31, 2016 | 43.28× | -1.4% |
| Dec 31, 2015 | 43.90× | +14.7% |
| Dec 31, 2014 | 38.27× | -2.8% |
| Dec 31, 2013 | 39.36× | +65.5% |
| Dec 31, 2012 | 23.79× | N/M |
Change is relative to the preceding observation. N/M values are excluded from averages.
Company P/E vs. peer trailing-12-month ratios
| Company | P/E ratio |
|---|---|
CMPUY This stockCompuGroup Medical SE & Co. KGaA | 38.98× |
BITGFBiotage AB (publ) | 40.34× |
DGWPFDrägerwerk AG & Co. KGaA | 11.01× |
MDRSFMedartis Holding AG | 78.50× |
LYPHFLuye Pharma Group Ltd. | 7.78× |
KKPCFKaken Pharmaceutical Co., Ltd. | 14.10× |
NPRRFNipro Corporation | 15.58× |
KSRBFKossan Rubber Industries Bhd | 15.95× |
BTTAYBiotest AG | 48.06× |
Peers are selected by the data provider. Business models and earnings definitions can differ.
Put the numbers in context
At 38.98×, CMPUY is 14.9% below its 10-observation annual average. A lower multiple can reflect a lower price, higher earnings, or weaker growth expectations—not necessarily a bargain.
The median of the 8 positive peer ratios above is 15.77×. Check growth, margins, debt, and earnings quality before interpreting the gap. A faster-growing business may justify a higher multiple.
One-off gains can temporarily lower P/E; unusual charges can raise it. Reported earnings and forward estimates answer different questions. Pair this view with return on equity and liquidity for a fuller picture.
Keep your research connected
Pull historical P/E into Excel or Google Sheets with Wisesheets. Build your own comparisons alongside the rest of your financial model.
Explore Wisesheets=WISE("CMPUY", "PE Ratio", "LQ")Share price 23 ÷ EPS 0.59 = 38.98×. Data is supplied by Financial Modeling Prep through Wisesheets. Quote feed updated Oct 15, 2026; this is not a real-time trading quote.
Annual and quarterly P/E observations are provided separately from the current quote. Averages use the latest 3, 5, or 10 annual observations, excluding missing and nonpositive ratios. Pre-IPO observations are omitted. These are period-end observations, not daily averages.
The current quote feed does not specify the exact EPS filing-period end or whether EPS is basic or diluted. We do not label it as forward P/E. Peer ratios are explicitly trailing-12-month (TTM) values. Historical observations do not include independently verified price and EPS inputs. Sources may update on different schedules; rounded inputs can produce small calculation differences. Historical comparisons describe past pricing, not an estimate of fair value.
The essentials behind the numbers.
CompuGroup Medical SE & Co. KGaA's current P/E is 38.98× based on the quote data last updated Oct 15, 2026. It represents the share price divided by reported earnings per share. Prices and earnings may refresh on different schedules.
Annual P/E uses earnings for a completed fiscal year. Trailing-12-month (TTM) P/E uses the latest four quarters, while forward P/E uses forecast earnings. These are not interchangeable. This page labels peer ratios as TTM and shows dated annual or quarterly historical observations; it does not show forward estimates.
N/M means not meaningful: the feed has no positive P/E for that observation. Negative or zero earnings should not be ranked as a low positive valuation multiple. N/M observations are excluded from the averages shown above.
Divide the share price by earnings per share (EPS). For example, a share price of 100 and EPS of 5 gives a P/E of 20×. This page uses the price and EPS supplied together in the quote when both are positive.
Price timestamps, EPS definitions, share classes, adjustments, and fiscal periods can differ. A forward P/E also uses forecast earnings rather than reported earnings. Compare the inputs and as-of dates before comparing two displayed ratios.
Not necessarily. The average describes previous market pricing, not fair value. Changes in earnings quality, growth expectations, debt, accounting, and business risk can justify a different multiple today.